SomaLogic

About

SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.

Boulder,Colorado,United States
251 - 500
http://www.somalogic.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $375M
Industries: Biotechnology,Health Care,Health Diagnostics,Medical Device
Founded date: Jan 1, 2000
Number Of Employee: 251 - 500
Operating Status: Active
Stock Symbol: nasdaq:SLGC
Legal Name: SomaLogic, Inc.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.

SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

18

$1.58B

SomaLogic has raised a total of $1.58B in funding over 2 rounds. Their latest funding was raised on Sep 1, 2021 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 1, 2021	Post-IPO Equity	$375M	11	—	—	Detail
Sep 1, 2021	IPO	$630M	—	—	—	Detail
Dec 23, 2020	Series A	$81M	11	—	—	Detail
Nov 25, 2020	Series A	$121M	11	Casdin Capital	—	Detail
Jan 3, 2018	Series Unknown	$200M	7	iCarbonX	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

37

SomaLogic is funded by 37 investors. iCarbonX and dRx Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
iCarbonX	Yes	Series Unknown
dRx Capital	Yes	Series A
ARK Investment Management	—	Post-IPO Equity
Casdin Capital	—	Post-IPO Equity
Corvex	—	Post-IPO Equity
Counterpoint Global	—	Post-IPO Equity
Farallon Capital Management	—	Post-IPO Equity
Illumina	—	Post-IPO Equity
Janus Henderson Investors	—	Post-IPO Equity
Novartis Pharma	—	Post-IPO Equity